FDA Vaccine Chief’s Exit Signals a Potential Shift in Regulatory Scrutiny The recent departure of Dr. Vinay Prasad, the Food and Drug Administration’s (FDA) vaccine chief, marks a potentially significant moment for the agency and the pharmaceutical industry. Prasad’s second exit from the FDA, confirmed on March 6, 2026, follows a period of controversial decisions … Read more
FDA Vaccine Chief Prasad’s Second Exit: A Sign of Shifting Regulatory Landscape? WASHINGTON — Vinay Prasad, a controversial figure at the Food and Drug Administration, is leaving the agency for a second time, marking the latest in a series of dramatic departures from the FDA. Prasad, director of the Center for Biologics Evaluation and Research … Read more
The Ongoing Quest for Female Sexual Wellness: Beyond the “Pink Pill” For decades, pharmaceutical solutions for male sexual dysfunction, like Viagra and Cialis, have been readily available. Yet, a comparable option for women has been a more elusive goal. Now, a new documentary, “The Pink Pill: Sex, Drugs & Who Has Control,” premiering on Paramount+, … Read more
The Shifting Landscape of GLP-1 Weight Loss: What Consumers Need to Know in 2026 The demand for GLP-1 medications like semaglutide and tirzepatide for weight loss continues to surge, but the path to accessing these treatments is becoming increasingly complex. Telehealth platforms like Sprout Health have emerged as popular options, but recent regulatory changes and … Read more
FDA Rejection of Rare Disease Therapy Sparks Debate Over Agency Direction A promising cell therapy developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals for a rare blood cancer faced a sudden reversal in its path to FDA approval. Internal reviewers had previously recommended clearance, yet the agency rejected the drug last month, citing insufficient clinical … Read more
The Dawn of Bespoke Medicine: How Individualized Treatments Are Reshaping Healthcare The Food and Drug Administration (FDA) recently released guidance paving the way for the approval of the first truly personalized medicines, designed to address a patient’s unique genetic makeup. This shift, spearheaded by FDA Commissioner Marty Makary and biologics chief Vinay Prasad, marks a … Read more
FDA Tightens the Leash on Livestock Antibiotics: What’s Next for Animal Health and Human Safety? The Food and Drug Administration (FDA) is taking a firmer stance on antibiotic utilize in food-producing animals, recently issuing guidance for drugmakers to define clear duration limits for medically important antibiotics. This move, announced February 12th by the FDA’s Center … Read more
FDA Reversal Paves the Way for Moderna’s mRNA Flu Vaccine The US Food and Drug Administration (FDA) has reversed its initial decision and will now review Moderna’s application for its innovative messenger RNA (mRNA)-based flu vaccine. This dramatic shift comes after a contentious back-and-forth with the pharmaceutical company, initially sparked by concerns over the clinical … Read more
RFK Jr. Targets Ultra-Processed Foods: A Potential Turning Point for the Food Industry Health and Human Services Secretary Robert F. Kennedy Jr. Has signaled a significant shift in federal oversight of the food industry, announcing plans to address concerns surrounding ultra-processed foods. This move, revealed on CBS’ “60 Minutes,” centers on a petition submitted by … Read more
FDA Rejection of Disc Medicine’s Bitopertin: A Turning Point for Fast-Tracked Drug Reviews? The Food and Drug Administration (FDA) on Friday rejected bitopertin, a therapy developed by Disc Medicine for the treatment of porphyria, a rare blood disorder causing extreme sensitivity to sunlight. This decision marks the first rejection under FDA Commissioner Marty Makary’s new … Read more